ATC code None ChemSpider 17588300 Formula C18H21F3N6O2 Molar mass 410.39 g/mol | PubChem CID 16654980 KEGG D10584 3D model (Jmol) Interactive image | |
 | ||
Buparlisib helps overcome endocrine resistance in metastatic breast cancer belle 2 trial results
Buparlisib (INN, codenamed BKM120) is an investigational small molecule orally-available pan-class I phosphoinositide 3-kinase inhibitor.
Contents
- Buparlisib helps overcome endocrine resistance in metastatic breast cancer belle 2 trial results
- Results of the belle 3 study of buparlisib for advanced breast cancer
- Clinical trials
- References
Results of the belle 3 study of buparlisib for advanced breast cancer
Clinical trials
In December 2015 it is reporting results for the phase III BELLE-2 clinical trial for advanced HR+/HER2 endocrine-resistant breast cancer. Encouraging results are reported in some sub-populations — e.g., some PI3K mutations.
References
Buparlisib Wikipedia(Text) CC BY-SA